Unexpected Beneficial Response to Etanercept Therapy in a
Hemodialysis Patient with Ankylosing Spondylitis
Journal Name:
- Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi
Keywords (Original Language):
| Author Name | University of Author | Faculty of Author |
|---|---|---|
Abstract (2. Language):
Erythropoietin (EPO) defi ciency is the main cause of renal anemia. However, chronic infl ammation
may be one of the important causes for EPO resistance in patients with renal anemia. Inhibition of
erythropoiesis by cytokines such as tumour necrosis factor alpha (TNF-α) may play an important role.
Etanercept, a recombinant dimeric fusion protein consisting of a TNF-α receptor ligand-binding region
linked to the Fc portion of human IgG, is approved for use in the treatment of ankylosing spondylitis.
Here, we present an end-stage renal failure patient with ankylosing spondylitis treated by etanercept and
observed no need for erythropoietin during etanercept treatment.
Bookmark/Search this post with
Abstract (Original Language):
Eritropoietin (EPO) eksikliği renal aneminin başlıca nedenidir. Bununla birlikte, kronik infl amasyon
renal anemili hastalarda EPO tedavisine karşı dirence yol açabilir. Tümör nekrozis faktör alfa (TNF-α)
gibi sitokinlerle eritropoezin inhibisyonu önemli rol oynayabilir. Bir TNF-α blokörü olan etanersept
ankilozan spondilit tedavisinde kullanılmaktadır. Biz bu raporda ankilozan spondilitli, etanersept ile
tedavi edilen ve bu tedavi süresince eritropoietin tedavisine gereksinim duymayan bir son dönem
böbrek yetmezlikli hastayı sunuyoruz.
FULL TEXT (PDF):
- 1